Tr1X's cells work the same way as naturally occurring Tr1 cells by homing to sites of inflammation, suppressing unwanted activity, and boosting production of antigen-specific Tr1 cells to reset the immune system and restore balance.
Tr1X was established to translate key academic discoveries in T-regulatory type 1 (Tr1) cell function and biology into commercially available treatments.
Tr1X is leveraging a unique population of regulatory T cells that overcome many of the current limitations with other Treg-based products. This includes several characteristics that are exclusively tied to Tr1 cells, which underpin all of our products.
Our cells are produced using a highly scalable and modular production process, allowing for the generation of multiple products at high purity levels and high dose quantities.
Our cells have a localized suppression feature-set, which includes high IL-10 production, expression of co-inhibitory receptors, inflammasome downregulation, tissue healing & wound repair.
Our cells home to sites of inflammation thanks to their array of chemokine receptors. They are highly stable and do not revert to effector cells even under inflammatory conditions.